For this study, we established a mouse glioblastoma treatment model and clearly describe the different mechanisms in anticancer immunity between WT1 peptide vaccine and anti-PD-1 antibody therapies under the same tumor microenvironment as well as the functions of the two immunotherapies at each step of the cancer-immunity cycle. This evidence concerns the gene WT1 and cancer.